MedPage Today

Assessing the Impact of BRCA Mutations on HR-Positive Metastatic Breast Cancer

Germline BRCA mutations have an adverse impact on both progression-free and overall survival in patients with hormone receptor-positive/HER2-negative metastatic ...
ascopubs.org

Construction of a control database for the filtering of germline mutations and false positive mutations in the detection of tumor somatic variations.

Comparison of the tumor mutation burden (TMB) analysis results between a targeted next-generation sequencing method and the conventional WES method. This is an ASCO Meeting Abstract from the 2018 ASCO ...
ascopubs.org

Spectrum of acquired KRAS mutations in driver mutation-positive non-small cell lung cancer.

Nivolumab (Nivo) plus ipilimumab (Ipi) 6-month treatment versus continuation in patients with advanced non-small-cell-lung cancer (aNSCLC): 3-year results of the IFCT-1701 DICIPLE phase 3 trial.
The American Journal of Managed Care

City of Hope’s Afkhami Discusses NSCLC With EGFR Exon 20 Insertion-Positive Mutations

Michelle Afkhami, MD, of City of Hope, joins The American Journal of Managed Care® (AJMC®) for a discussion on EGFR exon 20 insertion positive mutations in non-small cell lung cancer. Michelle Afkhami ...
Seeking Alpha

SELLAS Announces Positive Data from Preclinical Studies Indicating ASXL1 Mutations as Predictor of Response to SLS009 in Solid Cancers

- Preselection Method for Cancers Responding to SLS009: High Efficacy of SLS009 Observed in 67% of ASXL1 Mutated Solid Cancers vs 0% in Non-ASXL1 Mutated Cancers – - ASXL1 Mutations Predictably ...
Seeking Alpha

Ocugen, Inc. Announces Positive 2-Year Data Across Multiple Mutations from Phase 1/2 Clinical Trial of OCU400 —A Novel Modifier Gene Therapy for Retinitis Pigmentosa

MALVERN, Pa., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and ...